Therapy Areas: Infectious Diseases
Gilead Sciences Inc presents several new studies at ECCMIC 2022 and confirms Veklury activity in treating COVID-19
25 April 2022 -

Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) said on Sunday that it has updated the findings from two studies that provide further highlights the importance of Veklury (remdesivir) for the treatment of hospitalized and non-hospitalized patients with COVID-19.

The company revealed the first study retrospective observational analysis of the real-world treatment data from the Premier Healthcare Database consisted of 853,219 patients hospitalized with COVID-19 across the US.

An oral presentation of this real-world data analysis will be given on 25 April at 11:00 Western European Summer Time in Hall P at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022), added the company.

A separate study, which is a new post-hoc analysis of data from the Phase 3 PINETREE study, demonstrated that use of Veklury within five days of symptom onset or between five to seven days of symptom onset reduced hospitalizations in patients at high risk for severe COVID-19 disease. This post-hoc analysis was presented as a poster at ECCMID, disclosed the company.

Additionally, the company presented two additional studies from its COVID-19 clinical and real-world evidence programmes at the conference. Veklury was generally well tolerated, with a high proportion of participants showing clinical improvement and recovery.

Veklury is a nucleotide analog that directly inhibits viral replication inside of the cell by targeting the SARS-CoV-2 viral RNA polymerase.Veklury (remdesivir 100 mg for injection) is indicated for the treatment of COVID-19 in adults and pediatric patients (12 years of age and older and weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, concluded the company.

Login
Username:

Password: